Results from two trials of AbbVie have showed sustained progression-free survival (PFS) of VENCLYXTO/VENCLEXTA (venetoclax) combination therapy for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) with co-existing conditions, and relapsed/refractory (R/R) CLL.

Fresh six-year follow-up data from the Phase III CLL14 trial show improved results in previously untreated patients with CLL and co-existing conditions.

Patients who received fixed-duration venetoclax in combination with obinutuzumab continued to experience enhanced PFS and higher undetectable minimal residual disease (uMRD) rates during their treatment with fixed-duration venetoclax plus obinutuzumab in comparison with those receiving chlorambucil and obinutuzumab.

The findings also demonstrated significantly positive time to next treatment (TTNT) rates with venetoclax plus obinutuzumab as against chlorambucil plus obinutuzumab.

The differences in PFS and TTNT benefits between venetoclax-based treatment and chemoimmunotherapy were found to be continued across all risk groups, comprising patients with high-risk molecular CLL.

In this six-year evaluation, the trial did not find any new safety signals, with the most common grade three adverse events (AEs) in patients treated with venetoclax-based combination being neutropenia, thrombocytopenia, infusion-related reaction, among others.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, final results from the Phase III MURANO trial showed that R/R CLL patients who received two-year fixed-duration venetoclax and rituximab sustained significantly longer median PFS at 54.7 months in comparison with 17 months with bendamustine and rituximab after a median follow-up period of seven years.

The results further showed that seven-year overall survival (OS) rates were 69.6% for patients receiving the venetoclax-based combination as against 51% for those who were treated with bendamustine-based combination.

The majority of the patients who received the full two-year venetoclax-based combination achieved undetectable minimal residual disease (uMRD) at the end of their treatment. These patients also demonstrated improved PFS and OS in comparison with patients with detectable MRD.

The venetoclax-rituximab combination’s safety profile was found to be in line with the known safety profile of each individual therapy alone.